4,225 results on '"Anemia, Sickle Cell therapy"'
Search Results
2. COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study.
- Author
-
Anderson AR, Strouse JJ, Manwani D, Brandow AM, Vichinsky E, Campbell A, Leavey PJ, Nero A, Ibrahim IF, Field JJ, Baer A, Soto-Calderon H, Vincent L, Zhao Y, Santos JJS, Hensley SE, Mortier N, Lanzkron S, Neuberg D, and Abrams CS
- Subjects
- Humans, Male, Female, Adult, Adolescent, BNT162 Vaccine, Immunoglobulin G blood, Immunoglobulin G immunology, Antibodies, Viral blood, Antibodies, Viral immunology, Young Adult, Child, Spike Glycoprotein, Coronavirus immunology, Middle Aged, Prospective Studies, mRNA Vaccines, Anemia, Sickle Cell immunology, Anemia, Sickle Cell therapy, COVID-19 prevention & control, COVID-19 immunology, COVID-19 Vaccines adverse effects, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, SARS-CoV-2 immunology, Vaccination
- Abstract
Abstract: Children and adults with sickle cell disease (SCD) have increases in morbidity and mortality with COVID-19 infections. The American Society of Hematology Research Collaborative Sickle Cell Disease Research Network performed a prospective COVID-19 vaccine study to assess antibody responses and analyze whether messenger RNA (mRNA) vaccination precipitated any adverse effects unique to individuals with SCD. Forty-one participants received 2 doses of the Pfizer-BioNTech vaccine and provided baseline blood samples before vaccination and 2 months after the initial vaccination for analysis of immunoglobulin G (IgG) reactivity against the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike protein. Six-month IgG reactivity against the viral RBD was also available in 37 patients. Postvaccination reactogenicity was common and similar to the general population. There were no fevers that required inpatient admission. Vaso-occlusive pain within 2 to 3 days of first or second vaccination was reported by 5 participants (12%) including 4 (10%) who sought medical care. Twenty-seven participants (66%) were seropositive at baseline, and all 14 initially seronegative participants (34%) converted to seropositive after vaccination. Overall, mRNA vaccination had a good risk-benefit profile in individuals with SCD. This mRNA vaccine study also marks the first evaluation of vaccine safety and antibody response in very young children with SCD. This trial was registered at www.ClinicalTrials.gov as #NCT05139992., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation.
- Author
-
Riley JS, Berkowitz CL, Luks VL, Dave A, Cyril-Olutayo MC, Pogoriler J, Flake AW, Abdulmalik O, and Peranteau WH
- Subjects
- Animals, Mice, Female, Pregnancy, Immune Tolerance, Anemia, Sickle Cell immunology, Anemia, Sickle Cell therapy, CD3 Complex immunology, Antibodies, Monoclonal therapeutic use, T-Lymphocytes immunology, Humans, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Graft vs Host Disease immunology, Graft Survival immunology, Immunomodulation, Transplantation Tolerance immunology, Hematopoietic Stem Cell Transplantation methods, Disease Models, Animal
- Abstract
Abstract: In utero hematopoietic cell transplantation is an experimental nonmyeloablative therapy with potential applications in hematologic disorders, including sickle cell disease (SCD). Its clinical utility has been limited due to the early acquisition of T-cell immunity beginning at ∼14 weeks gestation, posing significant technical challenges and excluding treatment fetuses evaluated after the first trimester. Using murine neonatal transplantation at 20 days postcoitum (DPC) as a model for late-gestation transplantation (LGT) in humans, we investigated whether immune modulation with anti-CD3 monoclonal antibody (mAb) could achieve donor-specific tolerance and sustained allogeneic engraftment comparable with that of the early-gestation fetal recipient at 14 DPC. In allogeneic wild-type strain combinations, administration of anti-CD3 mAb with transplantation resulted in transient T-cell depletion followed by central tolerance induction confirmed by donor-specific clonal deletion and skin graft tolerance. Normal immune responses to third-party major histocompatibility complex and viral pathogens were preserved, and graft-versus-host disease did not occur. We further demonstrated the successful application of this approach in the Townes mouse model of SCD. These findings confirm the developing fetal T-cell response as a barrier to LGT and support transient T-cell depletion as a safe and effective immunomodulatory strategy to overcome it., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease.
- Author
-
Cliff ERS and Tessema FA
- Subjects
- Humans, United States, Anemia, Sickle Cell therapy, Anemia, Sickle Cell genetics, Genetic Therapy economics
- Published
- 2024
- Full Text
- View/download PDF
5. What is the future of digital tools to help manage pain in sickle cell disease patients?
- Author
-
Dampier C
- Subjects
- Humans, Pain etiology, Anemia, Sickle Cell complications, Anemia, Sickle Cell therapy, Pain Management methods
- Published
- 2024
- Full Text
- View/download PDF
6. Gene therapies on the horizon for sickle cell disease: a clinician's perspective.
- Author
-
Butt H and Tisdale JF
- Subjects
- Humans, Anemia, Sickle Cell therapy, Anemia, Sickle Cell genetics, Genetic Therapy methods
- Abstract
Introduction: Sickle cell disease (SCD) is a monogenic disorder that exerts several detrimental health effects on those affected, ultimately resulting in significant morbidity and early mortality. There are millions of individuals globally impacted by this disease. Research in gene therapy has been growing significantly over the past decade, now with two FDA approved products, aiming to find another cure for this complex disease., Areas Covered: This perspective article aims to provide a clinician's insight into the current landscape of gene therapies, exploring the novel approaches, clinical advances, and potential impact on the management and prognosis of SCD. A comprehensive literature search encompassing databases such as PubMed, Web of Science and Google Scholar was employed. The search covered literature published from 1980 to 2024, focusing on SCD and curative therapy., Expert Opinion: After careful evaluation of the risks and benefits associated with the use of gene therapy for affected patients, the need for a cure outweighs the risks associated with treatment in most cases of SCD. With advances in current technologies, gene therapies can increase access to cures for patients with SCD.
- Published
- 2024
- Full Text
- View/download PDF
7. Updates in Pediatric Sickle Cell Lung Disease.
- Author
-
Gillespie M, Afolabi-Brown O, Machogu E, Willen S, and Kopp BT
- Subjects
- Humans, Child, Anemia, Sickle Cell therapy, Anemia, Sickle Cell physiopathology, Anemia, Sickle Cell complications, Anemia, Sickle Cell diagnosis, Anemia, Sickle Cell epidemiology, Lung Diseases diagnosis, Lung Diseases therapy, Lung Diseases physiopathology, Lung Diseases etiology
- Abstract
Sickle cell lung disease presents a challenging care paradigm involving acute and chronic lower airway disease, sleep-disordered breathing, pulmonary vascular disease, and modification by environmental factors. Understanding the presentation, pathophysiology, and diagnostic approaches is essential for accurate identification and management. While significant progress has been made, there remains a need for research to develop effective treatments and interventions to decrease disease burden in these children. Additionally, the long-term impact of interventions on cardiopulmonary outcomes is unknown. Collaborative efforts among health care providers, researchers, advocacy groups, and policy makers are crucial to improving the lives of children with SCD., Competing Interests: Disclosure The authors have no relevant disclosures., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Reproductive Health Assessment and Reports of Fertility Counseling in Pediatric and Adolescent Patients with Sickle Cell Disease After Hematopoietic Cell Transplantation.
- Author
-
George SA, Veludhandi A, Xiang Y, Liu K, Stenger E, Arnold SD, Mehta A, Schirmer DA, Spencer JB, Guilcher GMT, Bhatia M, Abraham A, Gomez-Lobo V, Krishnamurti L, and Meacham LR
- Subjects
- Humans, Female, Male, Adolescent, Child, Adult, Young Adult, Transplantation Conditioning methods, Hematopoietic Stem Cell Transplantation adverse effects, Anemia, Sickle Cell therapy, Reproductive Health, Counseling, Fertility
- Abstract
Conditioning regimens for hematopoietic cell transplant (HCT) in patients with sickle cell disease (SCD) place patients at risk for reproductive health issues. The purpose of this study was to assess reproductive health and reports of fertility counseling in patients with SCD who received a transplant. This was a secondary analysis of gonadal hormone production, future infertility risk assessment, and parent-proxy/patient reports of fertility counseling in SCD transplant recipients who are currently pubertal and were enrolled in the Atlanta sites of the Sickle Cell Transplant Evaluation of Long-term and Late Effects Registry (STELLAR) between May 2017 and October 2023. Clinical information was abstracted from medical records and reproductive health survey data from the STELLAR database. Descriptive statistics were reported as median (interquartile range [IQR]) or percentages. There were 20 females and 12 males in the study population. Females were median (IQR) 19.6 (9.4) years old and males 20.8 (11.4) years old at the time of the study. Transplants most commonly occurred in the decade 2010 to 2019 at 10.7 (4.8) years old for females and 11.1 (4.1) years old for males. Most participants received bone marrow stem cells (95.0% females, 100.0% males) from matched sibling donors (90.0% females, 100.0% males). Participants received one of seven HCT conditioning regimens with cyclophosphamide equivalent doses ranging from 3388 to 9706 mg/m
2 . The majority of females (90.0%) had diminished ovarian reserve with low anti-Mullerian hormone levels, and 61.1% had premature ovarian insufficiency with two follicle-stimulating hormone levels (FSH) ≥40 mIU/mL post-HCT. All males had normal testosterone levels, but 63.6% had elevated FSH levels suggestive of impaired spermatogenesis post-HCT. Parent proxies (for patients <18 years old) and patients ≥18 years old completed surveys 9.0 years (5.2) and 7.9 years (9.3) since HCT in females and males respectively. Twenty-five percent of parent proxies and 45% of patients reported that they had not been informed by a healthcare provider of the risk of infertility post-transplant. There are high rates of gonadal dysfunction post-HCT, but many parent proxies and patients do not recall being told of the risk for future infertility. More effective methods of education are warranted to ensure SCD patients and their families clearly understand the risk for reproductive health issues post-HCT., (Copyright © 2024 The American Society for Transplantation and Cellular Therapy. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
9. The pervasive influence of systems of power on transition readiness for adult care in sickle cell disease: A qualitative study.
- Author
-
Prussien KV, Faust HL, Crosby LE, Smith-Whitley K, Barakat LP, and Schwartz LA
- Subjects
- Humans, Male, Female, Adolescent, Adult, Young Adult, Focus Groups, Caregivers psychology, Follow-Up Studies, Anemia, Sickle Cell therapy, Anemia, Sickle Cell psychology, Transition to Adult Care, Qualitative Research
- Abstract
Background: Adolescence and young adulthood are vulnerable developmental periods for individuals with sickle cell disease (SCD), particularly given the impact of social inequities, challenges with transitioning to adult healthcare services, and increased risk for morbidity and mortality. Systems of power, such as institutionalized and interpersonal manifestations of bias, could impact SCD transfer and engagement in adult care through their influence on healthcare transition readiness; yet research in this area is limited., Objective: To characterize how systems of power impact transition readiness factors described in the Social-ecological Model of AYA Readiness for Transition to Promote Health Equity (SMART-E) framework at the patient, caregiver, and practitioner levels., Methods: Pediatric adolescents and young adults (AYA), transferred AYA, caregivers, and practitioners participated in semi-structured focus groups and individual interviews examining health equity and systems of power during healthcare transition. Focus groups/interviews were transcribed and coded using a deductive approach via the updated SMART-E framework., Results: Ten pediatric AYA with SCD, nine transferred AYA with SCD, eight caregivers, and nine practitioners participated in a focus group or interview. Qualitative findings across reporters emphasize the impact of systems of power (e.g., racial bias and disease stigma) on knowledge, skills and self-efficacy, beliefs and expectations, goals and motivation, and emotions and psychosocial functioning at the patient, caregiver, and practitioner levels., Conclusion: Systems of power are prevalent with respect to transition barriers for AYA with SCD and their supports. Structural, institutional, and individual factors with potential to reduce the influence of systems of power should be further identified and targeted for intervention., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
10. Quantifying dilated perivascular spaces in children with sickle cell disease.
- Author
-
Karkoska KA, Gollamudi J, Sawyer RP, Woo D, and Hyacinth HI
- Subjects
- Humans, Female, Male, Child, Child, Preschool, Adolescent, Glymphatic System diagnostic imaging, Glymphatic System pathology, Cerebral Infarction diagnostic imaging, Cerebral Infarction etiology, Cerebral Infarction pathology, Anemia, Sickle Cell complications, Anemia, Sickle Cell pathology, Anemia, Sickle Cell therapy, Anemia, Sickle Cell diagnostic imaging, Magnetic Resonance Imaging
- Abstract
Sickle cell disease (SCD)-related neurological effects are particularly devastating. Dilated perivascular spaces (dPVS) are a well-described component of cerebral small vessel disease in older adults without SCD. However, the burden and association of dPVS with neurological complications in children with SCD have not been described. In this study, we used the international consensus criteria to quantify dPVS in the centrum semiovale and basal ganglia in T2-weighted magnetic resonance images (MRI) of children with SCD who were randomized as part of the Silent Cerebral Infarct Transfusion (SIT) trial. We examined the relationship between global and/or regional dPVS burden and presence or area of silent cerebral infarctions, hematological measures, demographic variables, and full-scale intelligence quotient (FSIQ) scores. The study included 156 SIT trial participants who had pre-randomization and study exit MRI. Their median age was 9.6 (5-15) years, 39% were female, and 94 (60%) participants had a high dPVS burden. Participants randomized to the blood transfusion arm and who had a high dPVS burden at baseline had a moderate decline in dPVS score over 36 months compared to no change in the observation group. On multivariable logistic regression, intelligence quotient was not associated with dPVS burden. Children with SCD included in the SIT trial have a high burden of dPVS compared to children without SCD. However, dPVS do not appear to have the same pathophysiology of silent cerebral infarcts. Further study is needed to determine both their etiology and clinical relevance., (© 2024 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
11. Withholding transfusion therapy in children with sickle cell disease with abnormal transcranial Doppler and normal magnetic resonance angiography: a retrospective analysis.
- Author
-
De Ligt LA, Fijnvandraat K, Biemond BJ, and Heijboer H
- Subjects
- Humans, Retrospective Studies, Child, Female, Male, Adolescent, Blood Transfusion methods, Withholding Treatment, Child, Preschool, Anemia, Sickle Cell therapy, Ultrasonography, Doppler, Transcranial methods, Magnetic Resonance Angiography methods
- Published
- 2024
- Full Text
- View/download PDF
12. SNAP: Supportive non-invasive ventilation for acute chest syndrome prevention for hospitalized children with sickle cell disease: Perspectives of patients, parents, and the healthcare team.
- Author
-
Cohen RT, Burrowes SAB, Williams CJ, Neri CM, Klings ES, Jones KC, Walkey AJ, and Drainoni ML
- Subjects
- Humans, Child, Male, Female, Adolescent, Patient Care Team, Qualitative Research, Hospitalization, Child, Preschool, Adult, Child, Hospitalized, Prognosis, Anemia, Sickle Cell therapy, Anemia, Sickle Cell complications, Acute Chest Syndrome prevention & control, Acute Chest Syndrome etiology, Acute Chest Syndrome therapy, Parents psychology, Noninvasive Ventilation methods
- Abstract
Rationale: Acute chest syndrome (ACS) often develops during hospitalizations for sickle cell disease (SCD) vaso-occlusive episodes and may be triggered by a combination of chest wall splinting, opioid use, hypoventilation, and atelectasis. In 2017, Boston Medical Center's general pediatric inpatient unit instituted the novel use of bi-level positive airway pressure (BiPAP) as "supportive non-invasive ventilation for ACS prevention" (SNAP) to prevent ACS and respiratory decompensation., Objective: The goals of this qualitative study were to identify perceived benefits, harms, facilitators, and barriers to use of SNAP., Methods: We conducted semi-structured key informant interviews at three sites with different levels of SNAP implementation (Site 1: extensive implementation; Site 2: limited implementation; Site 3: not yet implemented) regarding experiences with and/or perceptions of SNAP. Interviews and coding were guided by the Promoting Action on Research Implementation in Health Services (PARiHS) framework., Results: Thirty-four participants (physicians, nurses, respiratory therapists, child life specialists, psychologists, youth with SCD, and parents) completed interviews. Major themes included: (i) participants perceive BiPAP as effective at preventing ACS, and for those with medically stable ACS, for preventing respiratory decompensation. (ii) BiPAP use is appropriate on the general pediatric inpatient unit for medically stable patients with SCD. (iii) Improving the patient experience is the most important factor to optimize acceptance of BiPAP by patients and families., Conclusion/future Directions: SNAP is perceived as effective and appropriate for hospitalized pediatric patients with SCD. Improving the patient experience is the biggest challenge. These data will inform a future protocol for a multicenter hybrid effectiveness/implementation trial of SNAP., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
13. Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial.
- Author
-
Oteng-Ntim E, Oakley LL, Robinson V, Brien S, Joseph J, Sharif J, McCabe L, Thompson H, Awogbade M, Johns J, Brunetta DM, and Seed PT
- Subjects
- Humans, Female, Pregnancy, Adult, Exchange Transfusion, Whole Blood methods, Pregnancy Outcome, Anemia, Sickle Cell therapy, Feasibility Studies, Pregnancy Complications, Hematologic therapy, Pregnancy Complications, Hematologic prevention & control
- Abstract
Abstract: Serial prophylactic exchange blood transfusion (SPEBT) is increasingly used in sickle cell disease (SCD) pregnancy, despite a lack of robust evidence. The Transfusion Antenatally in Pregnant Women with Sickle Cell Disease (TAPS2) study assessed the feasibility and acceptability of conducting a definitive randomized controlled trial of SPEBT (intervention) vs standard care (control) in this population. Women aged ≥18 years with SCD, between 6+0 and 18+6 weeks of singleton gestation, were randomized 1:1 every 6 -10 weeks throughout pregnancy in 7 hospitals in England. The main outcomes were recruitment rate (primary outcome), acceptability, and retention. Secondary outcomes were safety and maternal/infant outcomes. In total, 194 women were screened over 42 months (extended because of the pandemic), 88 were eligible, and 35 (39.8%) consented to participate; 18 participants were randomized to intervention, and 17 to control. Follow-up data were collected on all participants. Twelve patients in the intervention group received at least 1 SPEBT, of these, 11 received ≥3. The remaining patient was withdrawn from SPEBT because of transfusion reaction. Sixteen control participants required at least 1 transfusion. There were no statistically significant differences in maternal, infant, and postnatal outcomes. A trend toward a lower incidence of vaso-occlusive crisis, preterm delivery, and improved birthweight was observed in the intervention. The study achieved satisfactory recruitment and retention, confirming its acceptability to participants. TAPS2 demonstrates that it is feasible to perform a definitive international trial of SPEBT in SCD pregnancy. These trials were registered at www.ClinicalTrials.gov as #NCT03975894 and International Standard Randomized Controlled Trial Number (www.isrctn.com; #ISRCTN52684446)., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
14. Elevating fetal hemoglobin: recently discovered regulators and mechanisms.
- Author
-
Khandros E and Blobel GA
- Subjects
- Humans, Animals, Anemia, Sickle Cell genetics, Anemia, Sickle Cell therapy, Anemia, Sickle Cell metabolism, beta-Thalassemia genetics, beta-Thalassemia therapy, beta-Thalassemia metabolism, Erythropoiesis genetics, beta-Globins genetics, beta-Globins metabolism, Fetal Hemoglobin genetics, Fetal Hemoglobin metabolism
- Abstract
Abstract: It has been known for over half a century that throughout ontogeny, humans produce different forms of hemoglobin, a tetramer of α- and β-like hemoglobin chains. The switch from fetal to adult hemoglobin occurs around the time of birth when erythropoiesis shifts from the fetal liver to the bone marrow. Naturally, diseases caused by defective adult β-globin genes, such as sickle cell disease and β-thalassemia, manifest themselves as the production of fetal hemoglobin fades. Reversal of this developmental switch has been a major goal to treat these diseases and has been a driving force to understand its underlying molecular biology. Several review articles have illustrated the long and at times arduous paths that led to the discovery of the first transcriptional regulators involved in this process. Here, we survey recent developments spurred by the discovery of CRISPR tools that enabled for the first time high-throughput genetic screens for new molecules that impact the fetal-to-adult hemoglobin switch. Numerous opportunities for therapeutic intervention have thus come to light, offering hope for effective pharmacologic intervention for patients for whom gene therapy is out of reach., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
15. A simplified G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model.
- Author
-
Li C, Anderson AK, Ruminski P, Rettig M, Karpova D, Kiem HP, DiPersio JF, and Lieber A
- Subjects
- Animals, Humans, Mice, Benzylamines, Cyclams pharmacology, Cyclams therapeutic use, Disease Models, Animal, Gene Editing, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cells metabolism, Heterocyclic Compounds pharmacology, Heterocyclic Compounds therapeutic use, Anemia, Sickle Cell therapy, Anemia, Sickle Cell genetics, Genetic Therapy methods, Granulocyte Colony-Stimulating Factor pharmacology, Hematopoietic Stem Cell Mobilization methods
- Abstract
Abstract: We have reported the direct repair of the sickle cell mutation in vivo in a disease model using vectorized prime editors after hematopoietic stem cell (HSC) mobilization with granulocyte colony-stimulating factor (G-CSF)/AMD3100. The use of G-CSF for HSC mobilization is a hurdle for the clinical translation of this approach. Here, we tested a G-CSF-free mobilization regimen using WU-106, an inhibitor of integrin α4β1, plus AMD3100 for in vivo HSC prime editing in sickle cell disease (SCD) mice. Mobilization with WU-106 + AMD3100 in SCD mice was rapid and efficient. In contrast to the G-CSF/AMD3100 approach, mobilization of activated granulocytes and elevation of the key proinflammatory cytokine interleukin-6 in the serum were minimal. The combination of WU-106 + AMD3100 mobilization and IV injection of the prime editing vector together with in vivo selection resulted in ∼23% correction of the SCD mutation in the bone marrow and peripheral blood cells of SCD mice. The treated mice demonstrated phenotypic correction, as reflected by normalized blood parameters and spleen size. Editing frequencies were significantly increased (29%) in secondary recipients, indicating the preferential mobilization/transduction of long-term repopulating HSCs. Using this approach, we found <1% undesired insertions/deletions and no detectable off-target editing at the top-scored potential sites. Our study shows that in vivo transduction to treat SCD can now be done within 2 hours involving only simple IV injections with a good safety profile. The same-day mobilization regimen makes in vivo HSC gene therapy more attractive for resource-poor settings, where SCD does the most damage., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. Studies of Exagamglogene Autotemcel - Age and Place. Reply.
- Author
-
Frangoul H, Hobbs WE, and Locatelli F
- Subjects
- Adolescent, Adult, Child, Humans, Young Adult, Anemia, Sickle Cell genetics, Anemia, Sickle Cell therapy, Developing Countries, Epidemiologic Factors, Internationality, beta-Thalassemia genetics, beta-Thalassemia therapy, Clinical Trials as Topic standards, Gene Editing methods, Patient Selection
- Published
- 2024
- Full Text
- View/download PDF
17. Studies of Exagamglogene Autotemcel - Age and Place.
- Author
-
Min J
- Subjects
- Humans, Anemia, Sickle Cell genetics, Anemia, Sickle Cell therapy, Child, Adolescent, Young Adult, Adult, Internationality, Age Factors, Developing Countries, Gene Editing methods, beta-Thalassemia genetics, beta-Thalassemia therapy, Clinical Trials as Topic, Patient Selection, Epidemiologic Factors
- Published
- 2024
- Full Text
- View/download PDF
18. Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease.
- Author
-
Sharma A, Selukar S, Bi Y, Merlocco A, Morin CE, Goode C, Rai P, Towbin JA, Hankins JS, Gottschalk S, Triplett B, and Johnson JN
- Subjects
- Humans, Male, Female, Adolescent, Child, Young Adult, Cardiomyopathies etiology, Cardiomyopathies therapy, Cardiomyopathies pathology, Adult, Myocardium pathology, Magnetic Resonance Imaging, Child, Preschool, Anemia, Sickle Cell therapy, Anemia, Sickle Cell pathology, Anemia, Sickle Cell complications, Hematopoietic Stem Cell Transplantation, Fibrosis
- Abstract
Abstract: Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
19. Cell and gene therapy accessibility.
- Author
-
Rouce RH and Porteus MH
- Subjects
- Humans, Anemia, Sickle Cell therapy, Anemia, Sickle Cell genetics, Neoplasms therapy, Neoplasms genetics, Cost-Benefit Analysis, Cell- and Tissue-Based Therapy economics, Genetic Therapy economics, Health Services Accessibility
- Abstract
Patients with devastating illnesses demonstrate incredible courage in battling their disease. Innovative cell and gene therapies (CGTs), built on decades of research, are changing the lives of those who suffer from conditions ranging from cancer to sickle cell disease to neurologic diseases. Although hailed for their promise and recognized for benefits that will exceed the costs, the high prices of CGTs ($300 thousand to $4 million per dose) leave these therapies out of reach for many. This accessibility problem will only be solved if academia, industry, investors, funders, regulators, and advocacy groups work together to put CGT breakthroughs in the hands of all who stand to benefit.
- Published
- 2024
- Full Text
- View/download PDF
20. Assessing Psychosocial Risk and Resilience to Support Readiness for Gene Therapy in Sickle Cell Disease: A Consensus Statement.
- Author
-
Hardy SJ, Crosby LE, Porter JS, Sil S, Valrie CR, Jonassaint CR, Bediako SM, Andrews C, Rivera M, Woolford T, and Coleman-Cowger VH
- Subjects
- Humans, Consensus, Adult, Female, Male, Risk Assessment, Anemia, Sickle Cell therapy, Anemia, Sickle Cell genetics, Anemia, Sickle Cell psychology, Genetic Therapy, Resilience, Psychological
- Abstract
Importance: The introduction of gene therapies into the clinical care landscape for individuals living with sickle cell disease (SCD) represents a momentous achievement with the potential to rewrite the story of the world's most prevalent heritable blood disorder. This disease, which was first described in 1910 and did not see a US Food and Drug Administration-approved therapeutic until 1998, is poised to be among the first to realize the promise of gene therapy and genome editing. However, the future of these treatments now rests on how evidence of safety, outcomes, and acceptance in clinical practice unfolds in SCD. Furthermore, historic injustices involving the exploitation of individuals from minoritized racial and ethnic groups in medical contexts necessitate extreme care in ensuring readiness among individuals with SCD considering genetic therapies., Objective: To address a gap in resources focused on patient readiness for gene therapy., Evidence Review: The Cure Sickle Cell Initiative organized the Patient Readiness and Resilience Working Group in September 2020. Membership was comprised of behavioral health clinicians and scientists with expertise in SCD, adults with lived experience with SCD, and a caregiver. Over 2 years, the working group developed consensus recommendations and created resources to guide implementation of pregene therapy patient readiness assessments. Recommendations centered on strategies to enhance delivery of education about gene therapy and assess knowledge and understanding, interest and motivation, and psychosocial risk and resilience factors., Findings: Five goals of a pregene therapy patient readiness assessment were identified: (1) gathering information about a patient's understanding of and perceived readiness for gene therapy; (2) encouraging an open dialogue; (3) providing a conceptualization of psychosocial factors that may influence participation in gene therapy; (4) identifying patient strengths that can be used to promote psychosocial well-being before, during, and after gene therapy; (5) identifying and addressing psychosocial risks., Conclusions and Relevance: Patient readiness and psychosocial factors will have tangible implications for the success of gene therapy at individual and collective levels. Health care institutions, industry, payers, policymakers, and clinicians all shoulder responsibility for ensuring that patients with SCD are adequately prepared for gene therapy and supported in ways that optimize readiness and access. Resources described here may be leveraged as a guide to support implementation of pregene therapy assessments of patient readiness and resilience in SCD.
- Published
- 2024
- Full Text
- View/download PDF
21. Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease.
- Author
-
Abdallah K, Huys I, Claes KJ, and Simoens S
- Subjects
- Humans, Belgium, Gene Editing methods, Gene Editing economics, CRISPR-Cas Systems, Genetic Therapy economics, Genetic Therapy methods, Cost-Benefit Analysis, Anemia, Sickle Cell genetics, Anemia, Sickle Cell drug therapy, Anemia, Sickle Cell economics, Anemia, Sickle Cell therapy, Antibodies, Monoclonal, Humanized economics, Antibodies, Monoclonal, Humanized therapeutic use, Budgets
- Abstract
Background and Objective: Treatment of sickle cell disease (SCD) has traditionally focused on symptomatic and preventative care. Recent advances in novel therapeutic developments, likely to be orphan-designated, are anticipated to carry a substantial price tag. This study assesses the potential budget impact of adopting disease-modifying treatments, crizanlizumab and voxelotor, and pioneering CRISPR gene-edited therapy, CTX001, in the Belgian healthcare system., Methods: The perspective of the Belgian healthcare payer (RIZIV-INAMI including patient copayments), a 5-year horizon with a 2-10% uptake of disease-modifying interventions, and a 2% uptake of CTX001 were considered. Data, encompassing target population, current (chronic and acute management, curative hematopoietic stem cell transplantation) and new (crizanlizumab, voxelotor, and CTX001) interventions, clinical effectiveness, adverse events, healthcare resource utilization, and associated costs, were gathered through a comprehensive literature review (first phase) and two Delphi panels involving hematologists (second phase). The cost difference between a "world with and without crizanlizumab, voxelotor, and CTX001" was calculated to obtain the budget impact. Three scenario analyses were conducted: a 5-13% and 4% uptake analysis, a 10-18% and 8% uptake analysis, respectively for disease-modifying treatments (crizanlizumab and voxelotor) and CTX001, and a 0% crizanlizumab uptake and managed entry agreements analysis . A ± 20% univariate sensitivity analysis was performed to test the robustness of the analysis., Results: The total five-year cumulative budget impact was estimated at €30,024,968, with 91% attributed to drug acquisition costs. The largest budget impact share was for CTX001 (€25,575,150), while crizanlizumab (€2,301,095) and voxelotor (€2,148,723) was relatively small. In scenarios one and three, a two-fold increase of the cumulative budget impact to €60,731,772 and a four-fold increase to €120,846,256 from the base case was observed. In scenario three, this budget impact decreased by 63% to €11,212,766. Patient population size, number of treated patients, and drug costs influenced the analysis the most, while discontinuation, acute crisis, and adverse event rates had comparatively minimal impact., Conclusions: Belgian decision-makers may consider alternative financing models, such as outcome-based risk-sharing agreements or annuities, to ensure sustainable coverage of these treatments. This study adheres to recommended practices for assessing budget impact of orphan drugs, distinguishing it from earlier studies with potentially weaker methodologies., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
22. Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health.
- Author
-
Nkya S, Masamu U, Kuona P, Kiguli S, Guindo A, Sarfo FS, Nnodu O, Wonkam A, Balandya E, and Makani J
- Subjects
- Humans, Biomedical Research, Anemia, Sickle Cell therapy
- Published
- 2024
- Full Text
- View/download PDF
23. Emergency department management of patients with sickle cell disease.
- Author
-
Newman B and Wilkerson RG
- Subjects
- Humans, Priapism therapy, Priapism etiology, Priapism diagnosis, Anemia, Sickle Cell therapy, Anemia, Sickle Cell complications, Emergency Service, Hospital
- Abstract
Sickle cell disease is a chronic hematologic disease that affects over 100,000 people in the United States. Many of these patients will present to the emergency department seeking treatment for an acute complication. Vaso-occlusive crisis, the most common recurring complication, can be difficult to manage because of the stigma patients face surrounding management of their pain. Patients with sickle cell disease presenting with conditions such as pain, infection, respiratory distress, stroke, or priapism must be given special consideration, as management can differ from that of the general population. This review evaluates the current guidelines and literature on acute complications related to sickle cell disease to dispel misconceptions about seemingly harmless interventions and provide clarification on those that are more controversial. Novel treatments that may have future impact on the management of patients with sickle cell disease are also reviewed.
- Published
- 2024
24. Health Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report.
- Author
-
Yates AM, Aygun B, Nuss R, and Rogers ZR
- Subjects
- Humans, Child, Adolescent, Primary Health Care, Anemia, Sickle Cell therapy
- Abstract
Sickle cell disease (SCD) is a group of complex genetic disorders of hemoglobin with multisystem manifestations. The scope of this clinical report is such that in-depth recommendations for management of all complications is not possible. Rather, the authors present an overview focused on the practical management of children and adolescents with SCD and the complications that are of particular relevance to pediatric primary care providers. References with detailed commentary provide further information. Timely and appropriate treatment of acute illness is critical, because life-threatening complications may develop rapidly. Specialized comprehensive medical care decreases morbidity and mortality during childhood. The provision of comprehensive care is a time-intensive endeavor that includes ongoing patient and family education, periodic comprehensive evaluations and other disease-specific health maintenance services, nursing support, psychosocial care, and genetic counseling. Ideally, this care includes comanagement by the pediatrician or other pediatric primary care provider and a team of specialist SCD experts: Hematologist, other pediatric specialists, advanced practice providers, nurse specialists, social workers, patient navigators, and educational liaisons., (Copyright © 2024 by the American Academy of Pediatrics.)
- Published
- 2024
- Full Text
- View/download PDF
25. Chronic automated red cell exchange therapy for sickle cell disease.
- Author
-
Zakieh A, Mercure-Corriveau N, Lanzkron S, Feng X, Vozniak S, Crowe EP, Rai H, Lawrence C, Bekkouri D, Goel R, Tobian AAR, and Bloch EM
- Subjects
- Humans, Female, Male, Retrospective Studies, Adult, Young Adult, Anemia, Sickle Cell therapy, Erythrocyte Transfusion
- Abstract
Background: The data to support chronic automated red cell exchange (RCE) in sickle cell disease (SCD) outside of stroke prevention, is limited, especially in adults., Study Design and Methods: A retrospective analysis was conducted of patients with SCD who were referred for chronic RCE at our institution over a 10-year period. Data that were evaluated included patient demographics, referral indications, and procedural details (e.g., vascular access, adverse events, etc.). In a subanalysis, the number of annual acute care encounters during 3 years of chronic RCE was compared with that in the year preceding the first RCE., Results: A total of 164 patients were referred for chronic RCE: median age was 28 years (interquartile range [IQR] = 22-36) at referral and 60% were female. Seventy (42.6%) were naïve to chronic transfusion (simple or RCE) prior to referral. The leading indications for referral were refractory pain (73/164, 44.5%) and iron overload (57/164, 34.7%). A total of 5090 procedures occurred during the study period (median = 19, IQR = 5-45). Of the 138 patients who had central vascular access, 8 (6%) and 16 (12%) had ≥1 central-line-related thrombosis and/or infection, respectively. Of those who were not RBC alloimmunized at initiation of RCE, 12/105 (11.4%) developed new antibodies during chronic RCE. In those 30 patients who were adherent to therapy for 3 years, there was no significant difference in acute care encounters following initiation of RCE., Conclusion: Prospective clinical trials are needed to determine which patients are most likely to benefit from chronic RCE and refine selection accordingly., (© 2024 AABB.)
- Published
- 2024
- Full Text
- View/download PDF
26. Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease.
- Author
-
Sharma A and John TD
- Subjects
- Humans, Anemia, Sickle Cell therapy, Anemia, Sickle Cell economics, Genetic Therapy economics, Genetic Therapy methods, Health Services Accessibility economics
- Abstract
Competing Interests: AS has received consultant fees from Spotlight Therapeutics, Medexus, Vertex Pharmaceuticals, Sangamo Therapeutics, and Editas Medicine. He is a medical monitor for a Resource for Clinical Investigations in Blood and Marrow Transplantation Conditioning SCID Infants Diagnosed Early clinical trial for which he receives financial compensation. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. AS is the St Jude Children's Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287), Novartis Pharmaceuticals (NCT04443907), and Beam Therapeutics (NCT05456880). The industry sponsors provide funding for the clinical trial, which includes salary support paid to AS's institution. AS has no direct financial interest in these therapies. AS is supported by a grant (1U01HL163983) from the National Institutes of Health/National Heart, Lung, and Blood Institute. The content of this Comment is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. TDJ has participated as an advisory board member and received consulting fees from Bluebird Bio and Vertex Pharmaceuticals. She is a medical monitor for BMT CTN 2001 GRASP study for which she receives compensation. TDJ is the Stanford site principal investigator of clinical trials for genome editing sponsored by Beam Therapeutics (NCT04443907). TDJ has no direct financial interest in this therapy. We thank Keith A Laycock for scientific editing of the Comment. We also thank Jennifer Adair, Fred Hutch Cancer Center, Jane Hankins, St Jude Children's Research Hospital, and Zainab Garba-Sani, Stanford University and NHS England, for offering critical insights on the topic and reviewing an early draft of the manuscript.
- Published
- 2024
- Full Text
- View/download PDF
27. Other Wounds Encountered in Clinical Practice.
- Author
-
Bolhack SM
- Subjects
- Humans, Aged, Wounds and Injuries therapy, Wounds and Injuries complications, Wounds and Injuries diagnosis, Leg Ulcer therapy, Leg Ulcer etiology, Anemia, Sickle Cell complications, Anemia, Sickle Cell therapy, Pyoderma Gangrenosum therapy, Pyoderma Gangrenosum diagnosis
- Abstract
This chapter delves into uncommon wounds including pyoderma gangrenosum, sickle cell disease ulcers, vasculitic wounds, Martorell hypertensive ischemic leg ulcers, and malignant ulcers. Emphasizing a multidisciplinary approach, it covers diagnostics, treatments, and challenges, with case studies illustrating complexities in managing these conditions. The discussion extends to radiation-related wounds, underscoring the need for patient-centered care, interdisciplinary collaboration, and realistic goal setting. Overall, the chapter navigates the intricacies of uncommon wounds, emphasizing the importance of tailored approaches for improved outcomes in patients with diverse underlying conditions., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Shift in emergency department utilization by frequent attendees with sickle cell disease during the COVID-19 pandemic: A multicentre cohort study.
- Author
-
Rech JS, Cohen A, Bartolucci P, Santin A, Chantalat Auger C, Affo L, Le Jeune S, Arlet JB, Boëlle PY, and Steichen O
- Subjects
- Humans, Male, Female, Adult, Middle Aged, France epidemiology, Pandemics, Cohort Studies, Young Adult, Adolescent, Patient Acceptance of Health Care statistics & numerical data, COVID-19 epidemiology, Anemia, Sickle Cell epidemiology, Anemia, Sickle Cell therapy, Emergency Service, Hospital statistics & numerical data, SARS-CoV-2
- Abstract
While the coronavirus disease-2019 (COVID-19) might have increased acute episodes in people living with sickle cell disease (SCD), it may also have changed their reliance on emergency department (ED) services. We assessed the impact of the COVID-19 pandemic and lockdowns on ED visits in adult SCD people followed in five French reference centres, with a special focus on 'high users' (≥10 visits in 2019). We analysed the rate of ED visits from 1 January 2015 to 31 December 2021, using a self-controlled case series. Among 1530 people (17 829 ED visits), we observed a significant reduction in ED visits during and after lockdowns, but the effect vanished over time. Compared to pre-pandemic, incidence rate ratios for ED visits were 0.59 [95% CI 0.52-0.67] for the first lockdown, 0.66 [95% CI 0.58-0.75] for the second and 0.85 [95% CI 0.73-0.99] for the third. High users (4% of people but 33.7% of visits) mainly drove the reductions after the first lockdown. COVID-19 lockdowns were associated with reduced ED visits. While most people returned to their baseline utilization by April 2021, high users had a lasting decrease in ED visits. Understanding the factors driving the drop in ED utilization among high users might inform clinical practice and health policy., (© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
29. Therapeutic plasma exchange for sickle cell disease acute complications: A systematic review.
- Author
-
Denoon RB, Soares Ferreira Junior A, Tuttle B, and Onwuemene OA
- Subjects
- Humans, Anemia, Sickle Cell therapy, Anemia, Sickle Cell complications, Plasma Exchange methods
- Published
- 2024
- Full Text
- View/download PDF
30. Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study.
- Author
-
Dovern E, Aydin M, Hazenberg MD, Tang MW, Suijk EM, Hoogendoorn GM, Van Tuijn CFJ, Kerkhoffs JL, Rutten CE, Zeerleder SS, de la Fuente J, Biemond BJ, and Nur E
- Subjects
- Humans, Adult, Female, Male, Prospective Studies, Middle Aged, Young Adult, Transplantation Chimera, Alemtuzumab therapeutic use, Alemtuzumab administration & dosage, Graft Rejection prevention & control, Graft vs Host Disease prevention & control, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation methods, Transplantation Conditioning methods, Siblings, Hydroxyurea therapeutic use, Hydroxyurea administration & dosage, Anemia, Sickle Cell therapy, Azathioprine therapeutic use, Azathioprine administration & dosage
- Abstract
Nonmyeloablative, matched sibling donor hematopoietic stem cell transplantation with alemtuzumab/total body irradiation (TBI) conditioning is a curative therapy with low toxicity for adults with sickle cell disease (SCD). However, relatively low donor chimerism levels and graft rejection remain important challenges. We hypothesized that adding azathioprine/hydroxyurea preconditioning will improve donor chimerism levels and reduce graft failure rate. In this prospective cohort study, we enrolled consecutive adult patients with SCD undergoing matched sibling donor transplantation at the Amsterdam UMC. Patients received azathioprine 150 mg/day and hydroxyurea 25 mg/kg/day for 3 months prior to alemtuzumab 1 mg/kg and 300 cGy TBI conditioning. Twenty patients with SCD (median age 26 years [range 19-49], 13 females) were transplanted. Median follow-up was 46.0 months (IQR 21.8-57.9). One-year overall survival and event-free survival (graft failure or death) were both 95% (95% confidence interval 86-100). Mean donor myeloid and T-cell chimerism 1-year post-transplant were 95.2% (SD ±10.6) and 67.3% (±15.3), respectively. One patient (5%) experienced graft failure without autologous regeneration, resulting in infections and death. All other patients had a corrected SCD phenotype and were able to discontinue sirolimus. Three patients were successfully treated with alemtuzumab (1 mg/kg) after the transplant because of declining donor chimerism and cytopenias to revert impending graft rejection. Toxicity was mostly related to sirolimus and alemtuzumab. One patient developed steroid-responsive grade II intestinal acute graft-versus-host disease. Collectively, preconditioning with azathioprine/hydroxyurea prior to nonmyeloablative matched sibling donor transplantation resulted in excellent event-free survival and robust donor T-cell chimerism, enabling the successful withdrawal of sirolimus. ClinicalTrials.gov: NCT05249452., (© 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
31. Sickle Cell Health Awareness, Perspectives, and Experiences (SHAPE) survey: Perspectives of adolescent and adult patients, caregivers, and healthcare professionals on the burden of sickle cell disease.
- Author
-
de Montalembert M, Anderson A, Costa FF, Inusa BPD, Jastaniah W, Kunz JB, Tinga B, Ingoli E, James J, Hartfield R, Beaubrun A, Lartey B, and Odame I
- Subjects
- Humans, Adult, Adolescent, Male, Female, Surveys and Questionnaires, Young Adult, Cost of Illness, Health Knowledge, Attitudes, Practice, Middle Aged, Anemia, Sickle Cell psychology, Anemia, Sickle Cell epidemiology, Anemia, Sickle Cell therapy, Caregivers psychology, Health Personnel psychology, Quality of Life
- Abstract
Objectives: Sickle cell disease (SCD) is an inherited disorder that causes lifelong complications, substantially impacting the physical and emotional well-being of patients and their caregivers. Studies investigating the effects of SCD on quality of life (QOL) are often limited to individual countries, lack SCD-specific QOL questionnaires, and exclude the caregiver experience. The SHAPE survey aimed to broaden the understanding of the global burden of SCD on patients and their caregivers and to capture the viewpoint of healthcare providers (HCPs)., Methods: A total of 919 patients, 207 caregivers, and 219 HCPs from 10, 9, and 8 countries, respectively, answered a series of closed-ended questions about their experiences with SCD., Results: The symptoms most frequently reported by patients were fatigue/tiredness (84%) and pain/vaso-occlusive crises (71%). Patients' fatigue/tiredness had one of the greatest impacts on both patients' and caregivers' QOL. On average, patients and caregivers reported missing 7.5 days and 5.0 days per month, respectively, of school or work. HCPs reported a need for effective tools to treat fatigue/tiredness and a desire for more support to educate patients on long-term SCD-related health risks., Conclusions: The multifaceted challenges identified using the SHAPE survey highlight the global need to improve both patient and caregiver QOL., (© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
32. Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.
- Author
-
Pecker LH and Cameron K
- Subjects
- Humans, Female, Pregnancy, Hematopoietic Stem Cell Transplantation adverse effects, Infertility, Female etiology, Infertility, Female therapy, Hydroxyurea therapeutic use, Infertility etiology, Infertility therapy, Anemia, Sickle Cell complications, Anemia, Sickle Cell therapy, Fertility Preservation methods, Counseling
- Abstract
Introduction: Sickle cell disease (SCD), its treatments and cures present infertility risks. Fertility counseling is broadly indicated for affected girls and women and fertility preservation may appeal to some. Several streams of evidence suggest that the reproductive lifespan of women with SCD is reduced. Pregnancy is associated with high miscarriage rates. There are enduring questions about the effects of highly effective hydroxyurea treatment on female fertility. Current conditioning regimens for gene therapy or hematopoietic stem cell transplant are gonadotoxic. Fertility preservation methods exist as non-experimental standards of care for girls and women. Clinicians are challenged to overcome multifactorial barriers to incorporate fertility counseling and fertility preservation care into routine SCD care., Areas Covered: Here we provide a narrative review of existing evidence regarding fertility and infertility risks in girls and women with SCD and consider counseling implications of existing evidence., Expert Opinion: Addressing fertility for girls and women with SCD requires engaging concerns that emerge across the lifespan, acknowledging uncertainty and identifying barriers to care, some of which may be insurmountable without public policy changes. The contemporary SCD care paradigm can offer transformative SCD treatments alongside comprehensive counselling that addresses fertility risks and fertility preservation opportunities.
- Published
- 2024
- Full Text
- View/download PDF
33. A severe case of delayed transfusion reaction in a patient with sickle cell disease while preparing for allogeneic stem cell transplant.
- Author
-
Amit M, Barsotti K, Carll T, Desai AV, and Kaviany S
- Subjects
- Humans, Transplantation, Homologous, Male, Female, Anemia, Sickle Cell therapy, Anemia, Sickle Cell complications, Hematopoietic Stem Cell Transplantation, Transfusion Reaction
- Published
- 2024
- Full Text
- View/download PDF
34. Endurance training improves oxygen uptake/demand mismatch, metabolic flexibility and recovery in patients with sickle cell disease.
- Author
-
Mougin L, Riccetti M, Merlet AN, Bartolucci P, Gellen B, Blervaque L, D'Humières T, Galactéros F, Emhoff CW, Féasson L, and Messonnier LA
- Subjects
- Humans, Male, Adult, Female, Young Adult, Energy Metabolism, Exercise Test, Oxygen metabolism, Exercise physiology, Anemia, Sickle Cell therapy, Anemia, Sickle Cell metabolism, Endurance Training methods, Oxygen Consumption
- Abstract
Patients with sickle cell disease (SCD) display lower slope coefficients of the oxygen uptake (V̇O2) versus work rate (W) relationship (delineating an O2 uptake/demand mismatch) and a poor metabolic flexibility. Because endurance training improves the microvascular network and increases the activity of oxidative enzymes, including one involved in lipid oxidation, endurance training might improve the slope coefficient of the V̇O2 versus W curve and the metabolic flexibility of SCD patients. Endurance training may also contribute to improve patients' post-exercise cardiopulmonary and metabolic recovery. Fifteen patients with SCD performed a submaximal incremental test on a cycle ergometer before (SIT1) and after (SIT2) 8 weeks of endurance training. Minute ventilation (V̇ E), ventilation rate, heart rate, V̇O2, carbon dioxide production (V̇CO2), respiratory exchange ratio, carbohydrate/lipid utilization and partitioning (including %Lipidox) and blood lactate concentration were measured during and after SIT1 and SIT2. At baseline, the slope coefficient of the V̇O2 versus W curve positively correlated with total hemoglobin, mean corpuscular hemoglobin and percentage of HbF. After training, the slope coefficient of the V̇O2 versus W curve was significantly higher and the increase in blood lactate concentration was delayed. If patients' energy metabolism apparently relied largely on carbohydrate sources during SIT1, %Lipidox tended to increase at low exercise intensities during SIT2, supporting a training-induced improvement of metabolic flexibility in patients with SCD. Post-exercise recovery of ventilation rate, V̇ E/V̇CO2, heart rate and blood lactate concentration was faster after training. We concluded that exercise training in patients with SCD: (i) ameliorated the oxygen uptake/ demand mismatch, (ii) blunted the metabolic inflexibility, and (iii) improved post-exercise cardiopulmonary and metabolic responses.
- Published
- 2024
- Full Text
- View/download PDF
35. Study of the antigenic characteristics of red blood cells units and their sickle cell disease recipients and the G6PD activity of transfused red blood cells units.
- Author
-
Le Gallo M, Moutereau S, Gentil M, and Pirenne F
- Subjects
- Humans, Male, Female, Adult, Blood Group Incompatibility immunology, Adolescent, Black People, Young Adult, Child, Isoantibodies blood, Isoantibodies immunology, Blood Donors, Blood Grouping and Crossmatching, Child, Preschool, Anemia, Sickle Cell therapy, Anemia, Sickle Cell immunology, Anemia, Sickle Cell blood, Glucosephosphate Dehydrogenase blood, Erythrocyte Transfusion adverse effects, Glucosephosphate Dehydrogenase Deficiency immunology, Erythrocytes immunology, Erythrocytes enzymology, Blood Group Antigens immunology
- Abstract
Introduction: Transfusion has a central place in the treatment of patients with sickle cell disease (SCD). Matching blood groups of red blood cell (RBC) units with the blood groups of the patient is essential to prevent alloimmunization and delayed hemolytic transfusion reaction. African ancestry donors have the best phenocompatibility with patients of the same origin, however their RBCs may present characteristic that can alter quality of the unit such as glucose-6-phosphate dehydrogenase (G6PD) deficiency. The objective is to analyze transfusion protocol, immunization rate and mismatch situations of SCD recipients and to evaluate the frequency of G6PD deficiency in RBCs units from African ancestry donors., Methods: Samples of units transfused to SCD patients were analyzed. Transfusion data were collected from institutional databases. The activity of G6PD was measured in the segment of the RBC units., Results: A total of 98 segments of units transfused to 37 SCD recipients in 41 transfusions episodes was collected. Among patients, 35.1% (n = 13) had no antibodies; 10.8% (n = 4) had antibodies against Fy
a /Fyb , Jka /Jkb , M/N, S/s; 21.6% (n = 8) against RH/K antigens. In all cases, the protocols were in line with the recommendations. G6PD deficiency was observed in 9 units, that were all collected from Afro-Caribbean donors., Conclusion: The transfusion protocol is established to prevent immunological reactions due to disparities in blood group antigens between donors and SCD recipients. However, the units of African ancestry donors, which allowed the best compatibility, displayed a high rate of G6PD deficiency. The storage and recovery impact of this deficiency must be evaluated., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
36. Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent.
- Author
-
Yu EA, Zacharias HU, Kelly S, and Vichinsky E
- Subjects
- Humans, Male, Female, Anemia, Sickle Cell therapy, Precision Medicine
- Published
- 2024
- Full Text
- View/download PDF
37. Rescue splenic artery embolization in an adult patient of sickle cell disease presented with acute splenic sequestration crisis.
- Author
-
Mohapatra S, Das PK, Rao PB, Nayak MK, Mane K, and Sahoo B
- Subjects
- Humans, Female, Young Adult, Splenic Diseases diagnostic imaging, Splenic Diseases therapy, Splenic Diseases etiology, Acute Disease, Tomography, X-Ray Computed, Embolization, Therapeutic methods, Anemia, Sickle Cell complications, Anemia, Sickle Cell therapy, Splenic Artery diagnostic imaging
- Abstract
Background: Splenic sequestration crisis is a potentially fatal complication of sickle cell disease, mainly seen in young children. Only a few case series describe the acute splenic sequestration crisis in adults and its management, which primarily consists of supportive care and, in some cases, splenectomy. Splenic artery embolization has seldom been described in sickle cell disease. This is probably the first case in which an adult with sickle cell disease presented with an acute splenic sequestration crisis was managed successfully through splenic artery embolization., Results: This 22-year-old female, a known case of sickle cell disease, presented with severe pain in the abdomen and low-grade intermittent fever for two days, secondary to an acute splenic sequestration crisis. The diagnosis of acute splenic sequestration was made based on clinical and blood parameters, ultrasonography, and computed tomography. Even with adequate supportive care and blood transfusions, the patient's condition worsened with a rapid fall in the hemoglobin and total platelet count. Considering splenectomy to be a high-risk procedure for this patient, a decision of rescue splenic artery embolization was taken, which was successful., Conclusion: Splenic artery embolization may be considered a lifesaving procedure in patients with acute splenic sequestration, where the risk of splenectomy can be high. Adequate post-procedure supportive care is vital for preventing complications., (© 2024. The Author(s), under exclusive licence to American Society of Emergency Radiology (ASER).)
- Published
- 2024
- Full Text
- View/download PDF
38. Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges - review article.
- Author
-
Youssry I and Ayad N
- Subjects
- Humans, Combined Modality Therapy, Anemia, Sickle Cell therapy, Anemia, Sickle Cell genetics, CRISPR-Cas Systems, Genetic Therapy methods, Gene Editing methods, Hematopoietic Stem Cell Transplantation
- Abstract
In 2022, sickle cell disease (SCD) continues to affect the lives of millions of people, being one of the most frequently inherited blood disorders worldwide. Recently, several new therapies have been FDA approved for the treatment of SCD. The complexity of the pathophysiology of sickling has given opportunity to the evolution of several modalities of therapies. Nonetheless, the potential for complementary targeting of HbS polymerization, vasocclusion, and other inflammatory pathways remains controversial. None of these drugs can be considered a single curative line of treatment. With the advancement of CRISPR/Cas9 technology, autologous transplant of gene-edited hematopoietic stem cells could possibly provide a cure for most patients with SCD. The advantage of this approach over the conventional stem cell transplantation is that it decreases the need for immuno-suppressive drugs and the risk of graft-versus-host disease. In addition, recent technological advances can reduce the off-target effects, but long-term monitoring is needed to ensure the reliability of these methods in the clinical setting. This review explores the efficacy and safety of combination therapies and contrasting this alternative with the challenges that exist with sickle cell gene therapy using CRISPR., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
39. Emergency department utilization before and during the COVID-19 pandemic among individuals with sickle cell disease.
- Author
-
Attell BK, Plaxco AP, Zhou M, Valle J, Reeves SL, Patel PN, Latta K, Smeltzer MP, and Snyder AB
- Subjects
- Humans, Retrospective Studies, Female, Male, Adult, Adolescent, Child, Middle Aged, Young Adult, Pandemics, Patient Acceptance of Health Care statistics & numerical data, SARS-CoV-2, United States epidemiology, Child, Preschool, Emergency Service, Hospital statistics & numerical data, Anemia, Sickle Cell epidemiology, Anemia, Sickle Cell therapy, COVID-19 epidemiology
- Abstract
Background: The emergency department (ED) is a vital source of healthcare for individuals living with sickle cell disease (SCD). Prior research indicates that during the COVID-19 pandemic some individuals with SCD avoided the ED for fear of acquiring COVID-19 or delayed visiting the ED by self-management of symptoms or pain crisis at home. The purpose of the current study was to understand ED utilization rates before and during the pandemic among individuals living with SCD., Methods: We conducted a retrospective cohort study using population-based SCD surveillance systems in California, Georgia, Michigan, and Tennessee to assess the impact of the pandemic on ED utilization among people with SCD by (1) analyzing trends in monthly ED utilization from January 2019 - December 2020, with specific attention given to immediate changes at the onset of the pandemic; and (2) calculating changes in the volume of utilization by comparing the total ED visits made from March - December 2020 to the same period in 2019, both overall and by demographic characteristics., Results: Across all states, a decline in ED utilization during the onset of the pandemic was seen, with the largest decline seen in those under age 10. By December 2020, utilization rates were higher than their lowest observed month of April 2020, but had not fully returned to pre-COVID levels. During the pandemic, ED visits in each state decreased by as much as 25%, and the number of people with any ED utilization decreased by as much as 26%., Conclusions: This study confirms and extends the existing literature related to the impact of the pandemic on healthcare utilization patterns in the US, in a unique population with increased healthcare needs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
40. Gaps during pediatric to adult care transfer escalate acute resource utilization in sickle cell disease.
- Author
-
Howell KE, Kayle M, Smeltzer MP, Nolan VG, Mathias JG, Nelson M, Anderson S, Porter JS, Shah N, and Hankins JS
- Subjects
- Humans, Male, Female, Adult, Adolescent, Young Adult, Child, Patient Acceptance of Health Care statistics & numerical data, Transition to Adult Care, Hospitalization, Emergency Service, Hospital statistics & numerical data, Patient Transfer, Health Resources statistics & numerical data, Anemia, Sickle Cell therapy
- Abstract
Abstract: Guidelines recommend transfer to adult health care within 6 months of completing pediatric care; however, this has not been studied in sickle cell disease (SCD). We hypothesized that longer transfer gaps are associated with increased resource utilization. Transfer gaps were defined as the time between the last pediatric and first adult visits. We estimated the association between varying transfer gaps and the rates of inpatient, emergency department (ED), and outpatient visits, using negative binomial regression. Health care utilization was evaluated in a mid-south comprehensive program for a follow-up period of up to 8 years (2012-2020) and was restricted to the first 2 years of adult health care. In total, 183 young adults (YAs) with SCD (51% male, 67% HbSS/HbSβ0-thalassemia) were transferred to adult health care between 2012 and 2018. YAs with transfer gaps ≥6 months compared with <2 months had 2.01 (95% confidence interval [CI], 1.31-3.11) times the rate of hospitalizations in the 8-year follow-up and 1.89 (95% CI, 1.17-3.04) when restricted to the first 2 years of adult health care. In the first 2 years of adult care, those with transfer gaps ≥6 months compared with <2 months, had 1.75 (95% CI, 1.10-2.80) times the rate of ED encounters. Those with gaps ≥2 to <6 months compared with <2 months had 0.71 (95 % CI, 0.53-0.95) times the rate of outpatient visits. Among YAs with SCD, a longer transfer gap was associated with increased inpatient and decreased outpatient encounters in adult health care and more ED encounters in the first 2 years of adult health care. Strategies to reduce the transfer gaps are needed., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. [Sickle cell disease - common and dangerous complications].
- Author
-
Björkman H, Fager Ferrari M, Arvanitakis A, and Kjellander C
- Subjects
- Humans, Acute Chest Syndrome therapy, Acute Chest Syndrome etiology, Adult, Stroke etiology, Stroke therapy, Child, Anemia, Sickle Cell complications, Anemia, Sickle Cell therapy
- Abstract
Sickle cell disease is a genetic disorder affecting hundreds of thousands of people worldwide. This article will focus on the most common and dangerous acute complications to sickle cell disease. Vaso-occlusive crisis is the most common manifestation of sickle cell disease. Rapid pain relief and treating the underlying cause are cornerstones of the treatment. Acute chest syndrome is the most common cause for intensive care unit admission and death among adult patients with sickle cell disease. The condition is treated as vaso-occlusive crises, but patients often need blood transfusions and respiratory support. Patients with sickle cell disease have an increased risk of stroke. Treatment follows the usual guidelines for stroke with the addition of blood- or exchange transfusions. Splenic sequestration is a rare but acute and life-threatening complication, most commonly seen in children. The condition can quickly lead to hypovolemic shock and the treatment aims to maintain adequate circulation and to treat the underlying cause.
- Published
- 2024
42. Case report: Persistent hypogammaglobulinemia and mixed chimerism after HLA class-II disparate-hematopoietic stem cell transplant.
- Author
-
de Gier M, Pico-Knijnenburg I, van Ostaijen-Ten Dam MM, Berghuis D, Smiers FJ, van Beek AA, Jolink H, Jansen PM, Lankester AC, and van der Burg M
- Subjects
- Humans, Female, Adolescent, Anemia, Sickle Cell therapy, Anemia, Sickle Cell immunology, B-Lymphocytes immunology, Transplantation Chimera, HLA Antigens immunology, HLA Antigens genetics, Hematopoietic Stem Cell Transplantation adverse effects, Agammaglobulinemia immunology, Agammaglobulinemia therapy
- Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for various hematological, immunological and metabolic diseases, replacing the patient's hematopoietic system with donor-derived healthy hematopoietic stem cells. HSCT can be complicated by early and late events related to impaired immunological recovery such as prolonged hypogammaglobulinemia post-HSCT. We present a 16-year-old female patient with sickle-cell disease who underwent HSCT with stem cells from a human leukocyte antigen (HLA) class-II mismatched family donor. While cellular recovery was good post-HSCT, the patient developed mixed chimerism and suffered from cervical lymphadenopathy, recurrent airway infections and cutaneous SLE. She presented with hypogammaglobulinemia and was started on immunoglobulin substitution therapy and antibiotic prophylaxis. B-cell phenotyping showed that she had increased transitional and naïve mature B cells, reduced memory B cells, and diminished marginal zone/natural effector cells. In-depth immunophenotyping and B-cell receptor repertoire sequencing ruled out an intrinsic B-cell defect by expression of activation-induced cytidine deaminase (AID), presence of somatic hypermutations and differentiation into IgG- and IgA-producing plasma cells in vitro. Immunohistochemistry and flow cytometry of lymph node tissue showed a clear block in terminal B-cell differentiation. Chimerism analysis of sorted lymph node populations showed that exclusively patient-derived B cells populated germinal centers, while only a minor fraction of follicular helper T cells was patient-derived. Given this discrepancy, we deduced that the HLA class-II disparity between patient and donor likely hinders terminal B-cell differentiation in the lymph node. This case highlights that studying disturbed cognate T-B interactions in the secondary lymphoid organs can provide unique insights when deciphering prolonged hypogammaglobulinemia post-HSCT., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 de Gier, Pico-Knijnenburg, van Ostaijen-ten Dam, Berghuis, Smiers, van Beek, Jolink, Jansen, Lankester and van der Burg.)
- Published
- 2024
- Full Text
- View/download PDF
43. Trainees' perspectives on sickle cell education: a qualitative needs assessment.
- Author
-
Prince EJ, Feder KJ, Calhoun C, Lee AI, Carroll CP, Restrepo V, and Van Doren L
- Subjects
- Humans, Male, Female, United States, Attitude of Health Personnel, Hematology education, Medical Oncology education, Adult, Clinical Competence, Education, Medical, Graduate, Anemia, Sickle Cell therapy, Needs Assessment, Qualitative Research, Focus Groups
- Abstract
Background: Sickle cell disease (SCD) exemplifies many of the social, racial, and healthcare equity issues in the United States. Despite its high morbidity, mortality, and cost of care, SCD has not been prioritized in research and clinical teaching, resulting in under-trained clinicians and a poor evidence base for managing complications of the disease. This study aimed to perform a needs assessment, examining the perspectives of medical trainees pursuing hematology/oncology subspecialty training regarding SCD-focused education and clinical care., Method: Inductive, iterative thematic analysis was used to explore qualitative interviews of subspecialty hematology-oncology trainees' attitudes and preferences for education on the management of patients with SCD. Fifteen trainees from six programs in the United States participated in 4 focus groups between April and May 2023., Results: Thematic analysis resulted in 3 themes: 1. Discomfort caring for patients with SCD. 2. Challenges managing complications of SCD, and 3. Desire for SCD specific education. Patient care challenges included the complexity of managing SCD complications, limited evidence to guide practice, and healthcare bias. Skill-building challenges included lack of longitudinal exposure, access to expert clinicians, and didactics., Conclusions: Variations in exposure, limited formal didactics, and a lack of national standardization for SCD education during training contributes to trainees' discomfort and challenges in managing SCD, which in turn, contribute to decreased interest in entering the SCD workforce. The findings underscore the need for ACGME competency amendments, dedicated SCD rotations, and standardized didactics to address the gaps in SCD education., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
44. Unpacking the utility of euvolemic automated transfusion in sickle cell disease.
- Author
-
Baykara Y, Nixon C, Pavlovich A, and Akgun Y
- Subjects
- Humans, Erythrocyte Transfusion methods, Blood Transfusion methods, Anemia, Sickle Cell therapy
- Published
- 2024
- Full Text
- View/download PDF
45. Medicaid Coverage in Early Childhood for Children With Sickle Cell Disease.
- Author
-
Horiuchi SS, Reeves SL, Plaxco AP, Peng HK, Zhou M, Kayle M, and Hulihan M
- Subjects
- Humans, United States, Child, Preschool, Female, Male, Insurance Coverage statistics & numerical data, Infant, Child, Anemia, Sickle Cell therapy, Medicaid
- Published
- 2024
- Full Text
- View/download PDF
46. A Cure for Sickle Cell Disease.
- Author
-
Walters M
- Subjects
- Humans, Anemia, Sickle Cell therapy
- Published
- 2024
- Full Text
- View/download PDF
47. Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program.
- Author
-
Richardson T, Rice M, Haumschild R, Hoffer D, Morana S, and Watkins J
- Subjects
- Humans, Anemia, Sickle Cell therapy, Anemia, Sickle Cell economics, Genetic Therapy economics, Hematologic Diseases therapy, Hemophilia A therapy, Hemophilia A drug therapy, Hemophilia A economics, Managed Care Programs economics
- Abstract
In this market insights program, AMCP brought together a panel of experts representing various stakeholders: national and regional health plans, integrated health care systems, employer benefits groups, clinical experts, the Centers for Disease Control and Prevention, and patient advocacy organizations. The objectives were to gain insights into the current and evolving treatments in hemophilia, sickle cell disease, and β-thalassemia; measure the effects of recently approved therapies on clinicians, payers, and patients; recognize emerging trends within the stop-loss market; address potential issues and obstacles related to monitoring and reporting outcomes; and identify concerns associated with both existing and emerging contracting and reimbursement models. This article aims to summarize expert perspectives on health care system challenges and strategies concerning the management of inherited blood disorders and to advance managed care professionals' understanding of their role in supporting care for these patients. The experts emphasized that when shaping coverage policies, a patient-centered approach is crucial, focusing on preserving organ function to maintain eligibility for future gene therapies among individuals with inherited blood disorders. These strategies, including benefit design modifications, specialized provider networks, and centralized mechanisms like registries, are vital for evaluating effectiveness, facilitating decision-making, and managing costs and risks associated with new and emerging treatment options for inherited blood disorders.
- Published
- 2024
- Full Text
- View/download PDF
48. Applying Comfort Theory to Improve Outcomes for People in Sickle Cell Crisis.
- Author
-
Elting JK, Di Cesare D, Layne J, Murthy M, and Mysyuk O
- Subjects
- Humans, Nursing Theory, Patient Comfort methods, Patient Comfort standards, United States, Anemia, Sickle Cell therapy, Anemia, Sickle Cell psychology
- Abstract
When people with sickle cell disease in vaso-occlusive crisis need hospitalization, they often experience fragmented and disparate treatment. Racial, gender, and socioeconomic treatment bias by providers, including nurses, is complicated by the current reactionary United States (US) controlled substance policies. To provide high-quality and respectful care, nurses can use Kolcaba's Comfort Theory as the framework for a holistic plan to assess, deliver individualized interventions, and evaluate outcomes for people experiencing vaso-occlusive crisis. Once in the electronic medical record, it can guide care during future hospitalizations. By refocusing on the nursing value of providing comfort care to individuals in distress, nurses can change treatment outcomes for clients., Competing Interests: Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the authorship and/or publication of this review.
- Published
- 2024
- Full Text
- View/download PDF
49. Patterns of primary and specialty care among children with sickle cell anemia.
- Author
-
Patel PN, Dombkowski KJ, Madden B, Raphael JL, Plegue M, Braun TM, and Reeves SL
- Subjects
- Humans, Child, Male, Child, Preschool, Female, Adolescent, Infant, United States, Michigan, Hematology, Follow-Up Studies, Medicaid statistics & numerical data, Prognosis, Anemia, Sickle Cell therapy, Primary Health Care statistics & numerical data
- Abstract
Background and Objective: National guidelines recommend that children with sickle cell anemia (SCA) be seen regularly by primary care providers (PCPs) as well as hematologists to receive comprehensive, multidisciplinary care. The objective is to characterize the patterns of primary and hematology care for children with SCA in Michigan., Methods: Using validated claims definitions, children ages 1-17 years with SCA were identified using Michigan Medicaid administrative claims from 2010 to 2018. We calculated the number of outpatient PCP and hematologist visits per person-year, as well as the proportion of children with at least one visit to a PCP, hematologist, or both a PCP and hematologist annually. Negative binomial regression was used to calculate annual rates of visits for each provider type., Results: A total of 875 children contributed 2889 person-years. Of the total 22,570 outpatient visits, 52% were with a PCP and 34% with a hematologist. Annually, 87%-93% of children had a visit with a PCP, and 63%-85% had a visit with a hematologist. Approximately 66% of total person-years had both visit types within a year. The annual rate ranged from 2.3 to 2.5 for hematologist visits and from 3.7 to 4.1 for PCP visits., Conclusions: Substantial gaps exist in the receipt of annual hematology care. Given that the majority of children with SCA see a PCP annually, strategies to leverage primary care visits experienced by this population may be needed to increase receipt of SCA-specific services., (© 2024 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
50. Foreword for The Role of Gene Therapy in Sickle Cell Disease and Parkinson's Disease.
- Author
-
Leikin JB
- Subjects
- Humans, Anemia, Sickle Cell therapy, Anemia, Sickle Cell genetics, Genetic Therapy methods, Parkinson Disease therapy, Parkinson Disease genetics
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.